Earnings Calls

Chubb completed its acquisition of a majority stake in Cigna's life and supplemental health businesses in Asia-Pacific in early 2026, expanding its non-P&C revenue base significantly. The company also raised its quarterly dividend to $0.91 per share in Q1 2026. Catastrophe exposure from the Los Angeles wildfires in January remains a key investor focus, with industry insured losses estimated above $30 billion.

Watch for the disclosed catastrophe loss figure from the January California wildfires and its impact on the combined ratio. Management commentary on premium rate trends in commercial lines will also be closely followed.

United Airlines withdrew its full-year 2026 guidance in early April, citing macroeconomic uncertainty and softening near-term booking trends, a move that pressured shares. The airline reported strong January and February revenue but flagged a deceleration in leisure demand. UAL has been expanding its international capacity, particularly trans-Atlantic routes, ahead of the summer travel season.

Watch for any reinstated or revised full-year EPS guidance range and Q2 capacity and revenue-per-available-seat-mile (RASM) outlook. Booking curve commentary for the summer travel period will be the most market-moving data point.

UnitedHealth Group's stock has surged approximately 37% over the past month, recovering from a multi-year low, following reports that the DOJ's antitrust investigation into its Optum unit is narrowing in scope. The company also reaffirmed its full-year 2026 adjusted EPS guidance range of $29.50–$30.00 at an investor event in March. Medical loss ratio pressure from elevated care activity remains the dominant operational concern.

Watch for the Q1 medical loss ratio — consensus expects approximately 86.5% — and any update or revision to full-year EPS guidance. Any new commentary on the DOJ Optum investigation will move the stock.

Lam Research has benefited from accelerating NAND and DRAM investment cycles, with major customers including Samsung and SK Hynix ramping etch and deposition equipment orders through early 2026. The company faces ongoing export control restrictions on shipments to certain Chinese customers, which management has previously estimated could impact annual revenue by several hundred million dollars. Shares are up 22.5% over the past month, reflecting broader semiconductor equipment sector strength.

Watch for the revenue figure relative to the $4.72 billion consensus estimate and the China revenue percentage disclosure. Forward-quarter guidance will be the primary stock mover given the 22.5% one-month run-up into the print.

Texas Instruments shares have risen 42% over the past month, driven by improving industrial and automotive end-market order signals and investor rotation into analog semiconductor names. The company has been executing a multi-year capacity expansion program, with its Sherman, Texas fab ramping incrementally. TXN's capital expenditure intensity remains elevated relative to historical norms as it builds out 300mm wafer capacity domestically.

Watch for Q2 revenue guidance — consensus is approximately $4.35 billion — and any commentary on industrial and automotive end-market order book recovery. Given the 42% one-month price move, the guidance range relative to expectations is the critical variable.

Comcast continued to lose broadband subscribers in Q4 2025, its fourth consecutive quarter of video and broadband net subscriber declines, as fixed wireless competition from T-Mobile and Verizon intensifies. The company announced plans to spin off its cable network portfolio — including MSNBC and CNBC — into a separate publicly traded entity, a transaction expected to close in mid-2026. Comcast's theme park segment remains a relative bright spot, with Epic Universe at Universal Orlando on track to open in May 2026.

Watch for broadband net subscriber additions or losses versus the consensus estimate of approximately negative 100,000. Any update on the cable network spinoff timeline or valuation parameters will also draw attention.

Procter & Gamble has faced sustained input cost pressure from higher commodity prices, particularly pulp, resin, and energy, through early 2026, while simultaneously navigating consumer trade-down dynamics in key categories. The company implemented targeted price increases in select markets in Q1 2026 and has accelerated productivity savings programs. P&G's organic sales growth decelerated to approximately 2% in Q4 2025 as volume and pricing contributions moderated.

Watch for organic sales growth rate — consensus expects approximately 2–3% — and any revision to the full-year fiscal 2026 EPS or sales growth outlook. Commentary on tariff-related cost exposure and pricing strategy will be closely monitored.